Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer

doi:10.3748/wjg.v22.i8.2415

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14195)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

1010

WORD

378

HTML

8095

Figures (1-2)

566

Tables (1-2)

261

Sum=10310

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

468

Download

822

Sum=1290

Publishing Process of This Article

Item

Count

Browse

1067

Download

1528

Sum=2595

Feb 28, 2016 (publication date) through Feb 2, 2025

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Feb 28, 2016; 22(8): 2415-2423
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2415

Table 2 Clinical trials of fiblobrast growth factor receptor 2-targeted therapy in gastric cancer

Trial	Study design	FGFRs status	Regimen	Response rate	Status
NCT01457846	Phase I/1^st	FGFR2amplification FISH +	AZD4547	38.5% (contained SD)	Conducted
SHINE	Phase II/1^st	FGFR2amplification FISH +	AZD4547 paclitaxel		Computed accural
NCT01719549	Phase II/2^nd	FGFR2 amplification	Dovitinib		Ongoing
NCT01921673	Phase I/II/2^nd	FGFR2 amplification	Dovitinib, docetaxel		Ongoing
NCT02052778	Phase I/II/2^nd	FGF/FGFR-Related Abnormalities	TAS-120		Ongoing
NCT02318329	Phase I/1^st	FGFR2b overexpression and FGFR2 amplification	FPA144		Ongoing

FGFR: Fiblobrast growth factor receptor; FISH: Fluorescence in situ hybridization; SD: Stable disease.

Citation: Yashiro M, Matsuoka T. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer. World J Gastroenterol 2016; 22(8): 2415-2423
URL: https://www.wjgnet.com/1007-9327/full/v22/i8/2415.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i8.2415